DBT plus mammo detects breast cancers with higher histologic grades
Digital breast tomosynthesis (DBT) plus synthesized mammography screening leads to higher detection of early-stage invasive breast cancers grades 2 or 3, according to research published December 5 in Radiology. A team led by Stefanie Weigel, MD, from the University of Münster in Germany, found in its subanalysis of the Tomosynthesis plus Synthesized Mammography (TOSYMA) study that this combined method detects more cancers than mammography alone. The group also found that women ages 60-70 with dense breasts had the highest breast cancer rate in the study. “These results suggest that DBT plus synthesized mammography scr...
Source: AuntMinnie.com Headlines - December 6, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: Subspecialties Breast Breast Imaging Source Type: news

Breast International Group (BIG) Highlights Innovations and Challenges in Breast Cancer Research, Exclusive Interview by Xtalks
In an interview by Xtalks, Dr. David Cameron, Chair of the Breast International Group (BIG), shared valuable insights into the current state of breast cancer research, emphasizing the role of clinical trials and the integration of patient perspectives in research. BIG's efforts, as... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 5, 2023 Category: Pharmaceuticals Tags: LIC Source Type: news

Addressing Chemo-Related Amenorrhea in Early BRCA Addressing Chemo-Related Amenorrhea in Early BRCA
Persistent chemotherapy-related amenorrhea (CRA) after treatment for breast cancer was common and associated with worse long-term quality of life among premenopausal women.MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 5, 2023 Category: Consumer Health News Tags: Hematology-Oncology Source Type: news

Scientists are creating ‘digital twins’ of breast cancer patients
The research programme, involving 13 Spanish institutions, such as hospitals and associations, collects genetic, physiological and behavioural data with wearable devices. Researchers in Spain are creating digital models of breast cancer patients to simulate and deliver tailor-made treatment plans.…#spanish #spain #miguelquintela #quintela #gonzálezcortijo #hairdresser #digitaltwins #ramos (Source: Reuters: Health)
Source: Reuters: Health - December 5, 2023 Category: Consumer Health News Source Type: news

RadNet to launch retail mammography clinic at Delaware Walmart
Imaging services provider RadNet will launch a mammography screening clinic December 8 at the Walmart Supercenter in Milford, Delaware. The launch is the first installation of RadNet’s new “MammogramNow” program, which aims to enhance breast health awareness and accessibility and includes the integration of AI mammography screening software, according to the company.“We believe RadNet currently performs close to five percent of all mammograms in the United States annually, and the pilot with Walmart is designed to provide even greater, convenient access for women,” said RadNet president and chief executive office...
Source: AuntMinnie.com Headlines - December 5, 2023 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Subspecialties Breast Imaging Source Type: news

Mechanics of breast cancer metastasis discovered, offering target for treatment
The most lethal feature of any cancer is metastasis, the spread of cancer cells throughout the body. New research, led by Penn State, reveals for the first time the mechanics behind how breast cancer cells may invade healthy tissues. The U.S … (Source: NSF News)
Source: NSF News - December 5, 2023 Category: Science Authors: NSF Source Type: news

Roche announces positive Phase III results for inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Phase III (INAVO120) results show that inavolisib in combination with palbociclib and fulvestrant significantly improved progression-free survival in the first-line settingPIK3CA mutations, found in approximately 40% of HR-positive breast cancers, are linked to tumour growth, disease progression, and treatment resistance1,2Data will be shared with health authorities and presented at an upcoming medical meetingBasel, 5 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance ®) a...
Source: Roche Media News - December 5, 2023 Category: Pharmaceuticals Source Type: news

AI algorithm flags interval breast cancer cases
AI could help tackle the challenge of identifying interval breast cancers, according to research presented November 30 at the RSNA 2023 annual meeting. In her talk, Tiffany Yu, MD, from the University of California, Los Angeles presented findings demonstrating how an AI algorithm correctly flagged minimal signs on digital mammography and digital breast tomosynthesis (DBT), as well as reading error misses. “AI can potentially play a role in identifying and reducing the interval breast cancer rate in U.S.-based screening programs,” Yu said. While recent studies based in Europe highlight how AI can reduce interval brea...
Source: AuntMinnie.com Headlines - December 5, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: Subspecialties Breast Breast Imaging Source Type: news

Roche announces positive Phase III results for inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Phase III (INAVO120) results show that inavolisib in combination with palbociclib and fulvestrant significantly improved progression-free survival in the first-line settingPIK3CA mutations, found in approximately 40% of HR-positive breast cancers, are linked to tumour growth, disease progression, and treatment resistance1,2Data will be shared with health authorities and presented at an upcoming medical meetingBasel, 5 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance ®) a...
Source: Roche Investor Update - December 5, 2023 Category: Pharmaceuticals Source Type: news

After Chemo, Breast Cancer Patient Develops Two Malignant Neoplasms
(MedPage Today) -- Be aware of the potential for secondary malignancy in relation to LCH diagnosis, researchers urge (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - December 5, 2023 Category: Dermatology Source Type: news

What Pigs and Squirrels Can Teach Us About Managing Pain
Over the past several decades, there have been many supporting studies of the health-promoting effects of an optimistic personality. Much research has been done on the connection between a high level of optimism and good health, described well in clinical psychologists Burel R. Goodin and Hailey W. Bulls’ 2014 research paper, appropriately titled, “Optimism and the Experience of Pain: Benefits of Seeing the Glass as Half Full.” The authors state that optimism “is linked to both enhanced physiological recovery and psychosocial adjustment to coronary artery bypass surgery, bone marrow transplant, post...
Source: TIME: Health - December 4, 2023 Category: Consumer Health News Authors: Dr. David B. Agus Tags: Uncategorized Books freelance Source Type: news

DBT shows how advanced cancers develop from longer intervals
Advanced cancers on digital breast tomosynthesis (DBT) occur with longer intervals from prior screening, a study presented November 30 at the RSNA 2023 annual meeting found.In her talk, Liane Philpotts, MD, from Yale University presented her team’s findings showing through DBT screening that until about 21 months, the rate of advanced cancers was stable. After that time point, it increased by nearly 10%.“With DBT screening, an interval of less than two years may help reduce the rate of advanced cancers,” Philpotts said. While breast cancer screening aims to detect nonlethal cancers early, many women do not adhere to ...
Source: AuntMinnie.com Headlines - December 4, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: Breast Breast Imaging Source Type: news

SABCS 2023 Highlights Breast Cancer De-Escalation SABCS 2023 Highlights Breast Cancer De-Escalation
From humble beginnings in 1977, 10,000 people are expected to attend this year ' s breast cancer meeting in San Antonio.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 1, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

CEM confirms effectiveness of cryoablation
CHICAGO -- Contrast-enhanced mammography (CEM) confirms the effectiveness of ultrasound-guided cryoablation and could serve as a reliable annual follow-up exam, findings presented November 26 at the RSNA annual meeting suggest. In her presentation, Federica di Naro, MD, from Azienda Ospedaliero-Universitaria Careggi in Florence, Italy discussed her team’s results, which showed that combining CEM and re-evaluation with biopsy in selected breast cancer histology proves the efficacy of ultrasound-guided cryoabaltion and CEM’s reliability.“CEM is a valuable tool to define the effectiveness of cryoablation,” di Naro sai...
Source: AuntMinnie.com Headlines - December 1, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: Womens Imaging Breast Imaging RSNA 2023 Source Type: news

TRUQAP (capivasertib), FDA Approved for the Treatment of Breast Cancer, Available at Biologics by McKesson
CARY, N.C., Dec. 1, 2023 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by AstraZeneca as a specialty pharmacy provider for TRUQAPTM (capivasertib). TRUQAP, which was approved by the U.S. Food and Drug Administration (FDA) on Nov. 17... (Source: McKesson News)
Source: McKesson News - December 1, 2023 Category: Information Technology Source Type: news